ACB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Aurora Cannabis Inc (ACB) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 to invest. The company faces significant challenges, including weak revenue growth, consistent net losses, and a lack of presence in the U.S. market. Despite a slight revenue increase in the latest quarter, the overall financial performance is poor, and the stock has lost substantial value over the years. Additionally, there are no strong technical or proprietary trading signals to suggest a favorable entry point.
The MACD is slightly positive but contracting, RSI is neutral at 37.565, and moving averages are converging, indicating no clear trend. The stock is trading near its support level of 3.511, but overall, the technical indicators do not suggest a strong buy signal.
The company has expanded into high-margin international markets like Germany, Poland, Australia, and the UK, which could provide some long-term growth potential.
Aurora Cannabis has lost 96% of its stock value since 2021, faces challenges in the competitive cannabis market, and has a negligible presence in the U.S. market. Analysts highlight weak revenue growth, consistent net losses, and potential shareholder dilution due to financing needs.
In Q3 2026, revenue increased by 6.79% YoY to $94.19 million. However, net income dropped by 93.63% YoY to $1.82 million, and EPS fell by 94.23% YoY to 0.03. Gross margin improved by 69.91% YoY to 5.93, but overall financial performance remains weak.
Analysts maintain a Buy rating but have lowered the price target from C$10 to C$9. While Aurora is recognized as a leading medical cannabis player in Canada and international markets, its financial struggles and lack of U.S. presence weigh heavily on its outlook.
